GLOW Stack: Evidence and Safety
What the GLOW stack contains, what GHK-Cu, BPC-157 and TB-500 studies actually tested, and where combination evidence and safety remain uncertain.

Quick Answer
The GLOW stack is a name for the combination of GHK-Cu, BPC-157 and TB-500. Ingredient research does not establish that this mixture improves skin, wound healing or recovery in people. The studies reviewed here examine individual substances, laboratory mechanisms or chemical identity; they do not test the three-part stack.
This page explains the three ingredients and the evidence gaps behind the skin and tissue-repair claims. For the four-ingredient version containing KPV, see the KLOW stack evidence review.
What Is in the GLOW Stack?
| Ingredient | Research context | Main evidence boundary |
|---|---|---|
| GHK-Cu | Copper-binding peptide studied in skin and tissue-remodeling research | Cosmetic or laboratory findings do not validate an injectable combination |
| BPC-157 | Experimental peptide studied in animal and cell models of injury | Rat tendon-cell findings do not establish human repair benefits |
| TB-500 | Name associated with a fragment of thymosin beta-4 | Findings for the full-length parent peptide cannot be assigned to the fragment |
The name alone is not a trial protocol. Interpreting a study requires the exact substance, formulation, route, comparator and outcome. A shared label does not show that a mixture matches a studied preparation.
GHK-Cu: Skin Research Versus Stack Claims
GHK-Cu is a copper complex of the three-amino-acid peptide glycine-histidine-lysine. A 2018 review discusses cell, animal and topical skin research involving collagen, tissue remodeling and gene expression.[]
These are different kinds of evidence. Changes in gene activity are biological signals, not measurements of improved appearance or healing in people. A topical cosmetic preparation also differs from an injectable formulation in exposure and safety questions. Neither category establishes how GHK-Cu behaves when combined with BPC-157 and TB-500.
Read the GHK-Cu research profile for the broader literature.
BPC-157: What a Tendon Study Actually Tested
A 2011 study examined rat Achilles tendon explants and cultured tendon fibroblasts. BPC-157 increased cell migration, tendon-explant outgrowth and cell survival under oxidative stress. It did not directly increase cell proliferation in the assay used. The authors linked the migration findings to FAK-paxillin signaling, a pathway involved in cell attachment and movement.[]
This was laboratory and explant research, not a human recovery trial. It did not test the GLOW mixture or demonstrate that adding copper peptide improves the result. Describing BPC-157 as supplying one proven stage of a combined healing sequence goes beyond these findings.
See the BPC-157 evidence review.
TB-500 Is Not Interchangeable With Thymosin Beta-4
Full-length thymosin beta-4 and its fragments are different research substances. An analytical study identified the acetylated seven-amino-acid fragment Ac-LKKTETQ in material labeled TB-500.[] That study established chemical identity in the sample; it was not a wound-healing or human safety trial.
Human findings involving a full-length thymosin beta-4 preparation do not establish efficacy for this fragment, a differently formulated product or the GLOW combination. The TB-500 and thymosin beta-4 profile provides additional context.
Does the Combination Have Evidence of Synergy?
The cited ingredient studies do not establish synergy. Synergy means a combination produces an effect beyond what would be expected from its components. Overlapping pathway descriptions cannot demonstrate that result.
A useful combination study would identify the exact ingredients and compare the mixture with an appropriate control and individual components. It would measure meaningful outcomes and adverse events. Without those comparisons, one cannot determine whether a mixture adds benefit, adds risk or changes nothing.
The evidence reviewed here therefore supports research questions about the ingredients, rather than a clinically validated GLOW protocol.
Safety and FDA Context
FDA identifies immune-reaction and peptide-impurity concerns for BPC-157, injectable GHK-Cu and the thymosin beta-4 fragment. Its risk summary describes limited human safety information; it does not establish that combining these substances is safe.[]
The July 23-24, 2026 PCAC meeting considered BPC-157- and TB-500-related bulk substances for the Section 503A compounding list. That process concerns compounding policy and is distinct from approval of a finished drug or evidence for this mixture.[] See the FDA peptide review hub for the meeting and regulatory distinctions.
GLOW Versus KLOW: What Changes?
KLOW adds KPV to the same three named ingredients. Adding an ingredient does not by itself establish stronger effects or broader clinical usefulness. The relevant question is whether the additional substance has been tested in the same formulation, population and combination.
Continue with the KLOW review for the KPV-specific evidence, or use Evaluating Peptide Research Claims to assess a study cited for either stack.
References
- 1.Pickart L, Margolina A. “Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data.” International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987 [PubMed]
- 2.Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. “The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration.” Journal of Applied Physiology. 2011;110(3):774-780. doi:10.1152/japplphysiol.00945.2010 [PubMed]
- 3.Esposito S, Deventer K, Goeman J, Van der Eycken J, Van Eenoo P. “Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.” Drug Testing and Analysis. 2012;4(9):733-738. doi:10.1002/dta.1402 [PubMed]
- 4.U.S. Food and Drug Administration. “Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.” 2026. [Link]
- 5.U.S. Food and Drug Administration. “July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” 2026. [Link]